PURPOSE: Inflammatory corneal hem- and lymphangiogenesis occurring both prior to as well as after penetrating keratoplasty significantly increase the risk for subsequent immune rejections. The purpose of this study was to analyze whether the blocking anti-VEGFR3 antibody mF4-31C1 is able to inhibit the outgrowth of pathologic new lymphatic vessels in a mouse model of suture-induced, inflammatory corneal neovascularisation, and whether this antibody specifically inhibits lymphangiogenesis without affecting hemangiogenesis. METHODS: Three interrupted 11-0 nylon sutures were placed into the corneal stroma of BALB/c mice (6 weeks old) and left in place for 7 days to induce neovascularisation. The treatment group (n = 9) received the anti-VEGFR3 antibody mF4-31C1 intraperitoneally on the day of surgery and 3 days later (0.5 mg/mouse). Control mice received an equal amount of control IgG solution. For immunohistochemistry, corneal flat mounts were stained with LYVE-1 as a specific lymphatic vascular endothelial marker and with CD31 as panendothelial marker. Morphometry was performed with the image analysis software analySIS;B (Soft Imaging Systems GmbH, Münster, Germany). To improve the objectivity and precision of the morphometrical analysis, we established a modified method using grey filter sampling on monochromatic pictures. RESULTS: The mF4-31C1 antibody-treated mice displayed nearly complete inhibition of lymphangiogenesis compared with IgG controls (p < 0.006). In contrast, there was no significant inhibitory effect observed with respect to blood vessel growth (p > 0.05). CONCLUSIONS: Inflammatory corneal lymphangiogenesis seems to depend on VEGFR3-signalling. By blocking this receptor the ingrowths of lymphatic vessels can be inhibited almost completely, and specifically without affecting hemangiogenesis. This may open new treatment options to promote (corneal) graft survival without affecting hemangiogenesis.
PURPOSE: Inflammatory corneal hem- and lymphangiogenesis occurring both prior to as well as after penetrating keratoplasty significantly increase the risk for subsequent immune rejections. The purpose of this study was to analyze whether the blocking anti-VEGFR3 antibody mF4-31C1 is able to inhibit the outgrowth of pathologic new lymphatic vessels in a mouse model of suture-induced, inflammatory corneal neovascularisation, and whether this antibody specifically inhibits lymphangiogenesis without affecting hemangiogenesis. METHODS: Three interrupted 11-0 nylon sutures were placed into the corneal stroma of BALB/c mice (6 weeks old) and left in place for 7 days to induce neovascularisation. The treatment group (n = 9) received the anti-VEGFR3 antibody mF4-31C1 intraperitoneally on the day of surgery and 3 days later (0.5 mg/mouse). Control mice received an equal amount of control IgG solution. For immunohistochemistry, corneal flat mounts were stained with LYVE-1 as a specific lymphatic vascular endothelial marker and with CD31 as panendothelial marker. Morphometry was performed with the image analysis software analySIS;B (Soft Imaging Systems GmbH, Münster, Germany). To improve the objectivity and precision of the morphometrical analysis, we established a modified method using grey filter sampling on monochromatic pictures. RESULTS: The mF4-31C1 antibody-treated mice displayed nearly complete inhibition of lymphangiogenesis compared with IgG controls (p < 0.006). In contrast, there was no significant inhibitory effect observed with respect to blood vessel growth (p > 0.05). CONCLUSIONS: Inflammatory corneal lymphangiogenesis seems to depend on VEGFR3-signalling. By blocking this receptor the ingrowths of lymphatic vessels can be inhibited almost completely, and specifically without affecting hemangiogenesis. This may open new treatment options to promote (corneal) graft survival without affecting hemangiogenesis.
Authors: Kazuichi Maruyama; Masaaki Ii; Claus Cursiefen; David G Jackson; Hiroshi Keino; Minoru Tomita; Nico Van Rooijen; Hideya Takenaka; Patricia A D'Amore; Joan Stein-Streilein; Douglas W Losordo; J Wayne Streilein Journal: J Clin Invest Date: 2005-09 Impact factor: 14.808
Authors: T Mäkinen; T Veikkola; S Mustjoki; T Karpanen; B Catimel; E C Nice; L Wise; A Mercer; H Kowalski; D Kerjaschki; S A Stacker; M G Achen; K Alitalo Journal: EMBO J Date: 2001-09-03 Impact factor: 11.598
Authors: Tina Dietrich; Jasmine Onderka; Felix Bock; Friedrich E Kruse; Dörte Vossmeyer; Roland Stragies; Grit Zahn; Claus Cursiefen Journal: Am J Pathol Date: 2007-07 Impact factor: 4.307
Authors: Sebastian F Schoppmann; Alexandra Fenzl; Monika Schindl; Thomas Bachleitner-Hofmann; Katalin Nagy; Michael Gnant; Reinhard Horvat; Raimund Jakesz; Peter Birner Journal: Breast Cancer Res Treat Date: 2006-03-23 Impact factor: 4.872
Authors: V Joukov; K Pajusola; A Kaipainen; D Chilov; I Lahtinen; E Kukk; O Saksela; N Kalkkinen; K Alitalo Journal: EMBO J Date: 1996-04-01 Impact factor: 11.598
Authors: Peter Baluk; Alicia Adams; Keeley Phillips; Jennifer Feng; Young-Kwon Hong; Mary B Brown; Donald M McDonald Journal: Am J Pathol Date: 2014-03-11 Impact factor: 4.307
Authors: Tina Dietrich; Felix Bock; Don Yuen; Deniz Hos; Björn O Bachmann; Grit Zahn; Stanley Wiegand; Lu Chen; Claus Cursiefen Journal: J Immunol Date: 2009-12-16 Impact factor: 5.422
Authors: P Zimmermann; T Dietrich; F Bock; F K Horn; C Hofmann-Rummelt; F E Kruse; C Cursiefen Journal: Br J Ophthalmol Date: 2009-07-23 Impact factor: 4.638